The Coronavirus

A previously unknown beta-Coronavirus was discovered through unbiased sequencing in samples from pneumonia patients.

Learn More

TMRS Backstory

TMRS was investigating the specific pattern of transmissions experienced by COVID-19, during R&D on its saliva-inducing Product #1, when Company President / Formulator, Dr. PJ laRive, PhD, a retired NASA scientist, discovered that our intellectual property could potentially suppress the spread of COVID-19.

Learn More

The Science

TMRS Research & Development’s theorem is a combination of a specific protein, delivered into the human mouth, which makes a natural saliva and protein referred to as Lactoferrin. This protein has been regularly analyzed and captured as an iron-binding protein and is secreted by serous salivary glands.

Learn More

Clinical Trials

In examining the safety and effectiveness of TMRS’s Cv-19 SRM oral solution, Dr. Sergey Sorin, MD, Director of the Shealy-Sorin Wellness Institute, sponsored TMRS’s Phase-1 Clinical Trials, conducting a double-blind, placebo-controlled study of 80 test subjects.

Learn More

The Coronavirus

Human airway epithelial cells were used to isolate a novel Coronavirus, named COVID-19, which formed another clade within the subgenus Sarbecovirus, Orthocoronavirinae subfamily. Different from both MERS-CoV and SARS-CoV, the COVID-19 strain is the seventh member of the family of Coronaviruses to infect humans.

It is well documented that the COVID-19 strain is transmitted through force-flow coughing and sneezing. Thus, stopping the disease will be best achieved by prevention at the source. TMRS had discussions with public health officials in China, and they agreed regarding the need to find the key lever at the source of this strain of the Coronavirus, through a greater understanding of the transmission patterns.

TMRS Backstory

Since TMRS sources much of its chemicals and raw materials from China, and moreover since some of the Company’s purveyors are located in the affected areas, the Chinese Center for Disease Control (CDCC) requested that our lab test all of our raw materials for Coronavirus infestation.

In order to facilitate said testing, the CDCC sent Dr. laRive a 3D modeling sequence for COVID-19 [see figure 2 – Glycoprotein Spike (S)]. In applying TMRS’s product specifications to the 3D rendering, Dr. laRive noticed, 1) that Glycoprotein Spike (S) was dismantled in the 3D modeling, potentially providing a control factor for the uncontrolled force-flow coughing and sneezing, associated with the COVID-19’s transmission.

In short, our technology would potentially stop COVID-19’s associated bronchio-influenza  symptoms. According to a letter from the World Health Organization (“WHO”), lauding the promising nature of Dr. la Rive research, TMRS’s resulting product could eliminate COVID-19’s spread, by as much as 20%.  As a result, Dr. la Rive is now in moment-to-moment with the WHO and CDCC, as they seek access our IP.

The Science

It has a bacteriostatic activity that the 3-D modeling recognized as positive, with the virus being negative, and thus engaging the Glycoprotein Spike (S).  In order to facilitate said testing, the CDCC sent Dr. laRive a 3-D modeling sequence for COVID-19 [see figure 2 – Glycoprotein Spike (S)]. In applying TMRS’s product specifications to the 3-D rendering, Dr. laRive noticed, 1) that Glycoprotein Spike (S) was dismantled in the 3-D modeling, potentially providing a control factor for the uncontrolled force-flow coughing and sneezing, associated with the COVID-19’s transmission.
The Glycoprotein Spike (S) is a multifunctional molecular machine that mediates coronavirus entry into host cells. It first binds to a receptor on the host cell surface, through its S1 subunit (recombinant S1 subunit of human SARS coronavirus (isolate: WH20).

The spike comprises 665 aminoacids and has a predicted molecular mass of 74.4 kDa, and then fuses to viral and host membranes, through its S2 Subunit. (The S2 Subunit of QX-type Infectious Bronchitis Coronavirus Spike Protein Is an essential determinant of COVID-19.) Two domains in S1, stemming from different Coronaviruses, are recognized a variety of host receptors, leading to viral attachments.

The spike protein exists in two structurally distinct conformations: pre-fusion and post-fusion. The transition from pre-fusion to post-fusion conformation of the spike protein must be triggered, leading to membrane fusion. The term, R0 (pronounced, “R-naught”) associates a number, indicating how many people that one person infected with the virus is likely to infect.

For example, if R0 is 3, then on average, every confirmed case of COVID-19 will lead to three other people infected with the virus. Although this metric seems simple to conceptualize, the margin for computational error is high, making it is difficult to calculate and tricky to interpret.

Clinical Trials

Additionally, Dr. Sorin also oversaw a pre-trial study of 20 test subjects.

While the Company has not yet completed the full statistical analysis, we can report that none of the 100 participants reported any adverse side effects, and none exhibited any evidence of COVID-19 symptoms or infection.  Moreover, test subjects who complained of sinus issues noted a significant reduction in their symptoms as a result of taking TMRS’s COVID-19 SRM.